Development

Feliza Mirasol is the science editor for 

Articles

The partnership will use ViaNautis’ proprietary polyNaut technology platform to develop genetic medicines that can precisely target tissue types.

Lilly and ViaNautis Bio Partner on Development of Novel Therapeutics Delivering Genetic Cargo

Videos

At AAPS PharmSci 360, Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, discussed lipid-based formulations and tackling bioavailability challenges for oral biologics.

AAPS PharmSci 360: LBFs and Tackling Oral Biologic Formulations

Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, spoke on recent challenges and trends in softgel formulations. 

AAPS PharmSci 360: Challenges and Trends in Softgel Formulations

Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.”

AAPS PharmSci 360 2024: Drug Delivery in Early Development

Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.

Prioritizing Formulation Strategies for Temperature-Sensitive Biotherapeutics

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

A new Center of Excellence will be established at PCI Pharma Services’ location in Rockford, Ill., and two sites in Ireland will also benefit from the investment.

PCI Pharma Invests More Than $365 Million in New and Existing Facilities in US and EU

Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

Formulating Inhaled Medicines

The company is referring to its search for innovative approaches as crowdsourcing and will award at least one cash prize.

Angelini Pharma Seeks Solutions for New Drug Delivery Systems and Treatments

Joe Petroziello is Executive Vice President, Head of Global Medical Affairs & Corporate Development at MJH Life Sciences.

At BIO 2024 in San Diego, John Dunlop, PhD, chief scientific officer at Aliada Therapeutics, sat down for an interview with Pharmaceutical Technology to discuss the firm’s MODEL platform and its potential impact on therapeutic delivery for brain-related conditions. 

Therapeutic Delivery for Brain-Related Conditions

CordenPharma has partnered with Spain-based Certest to develop ionizable lipids for LNP formulations.